SAFETY OF RAZI COV PARS VACCINE AGAINST OMICRON

Dr. Mojtaba Noofeli, Director of the Razi Cov Pars vaccine
clinical trial site highlighted that the Razi vaccine platform is a recombinant
protein, its effectiveness on other strains has been determined and can be
effective in the face of the new omicron strain. Studies led by WHO are
currently underway on the effectiveness of existing vaccines against the new
Omicron strain, but the final results have not yet been published. In order to
perform the neutralization test and the antibody-induced function of the
vaccine on the new strain, it is first necessary to isolate and culture the
virus and provide it for testing, which has not been officially isolated in
Iran at present, he added.

Dr. Noofeli clarified about the injection of Razi vaccine as
a booster dose and point out that a study is currently underway and the results
of which will be officially announced next week. In the study, Razi vaccine is
injected as a booster dose of Astrazenka, Sputnik, Sinofarm, Barakat vaccines
and Razi Cov Pars vaccine itself, which is very safe in terms of harmlessness
and has good antibody titers. The Director of Razi Cov Pars vaccine clinical
trial site added, "the clinical study of Razi Cov Pars vaccine for the age
group of 12 to 18 years has received a clinical study license, which will start
next week." He pointed out that the clinical study phase of people aged 12
to 18 will be completed in a few weeks, as we have a good reception from the
participants of this age group. Due to the young ages of these people, we can
see a good immune response by injecting two doses of the vaccine, but if
necessary, and examining this age group, we can also consider the intranasal
dose. Although in this group as well as in older age groups, injecting two
doses of vaccine is sufficient for effective immunity, but in order to
interrupt the virus transmission cycle in pandemic conditions, using an
intranasal dose will be very effective.

Dr. Noofli underlined that 5 million doses of vaccine are
ready for delivery, which we can be delivered as soon as possible, according to
the needs of the country and the request of the Ministry of Health. Fortunately,
due to the excellent results of this vaccine in the pre-clinical and clinical
study phases I,II and III, there are now inquiries from some countries for the
export of Razi Cov Pars vaccine, and negotiations are underway in this regard.

http://en.areeo.ac.ir/news/safety-of-razi-cov-pars-vaccine-against-omicron